Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (Nasdaq:BCRX) will present at two virtual healthcare conferences: the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. ET, and the JMP Securities Life Sciences Conference on June 17, 2021, at 1:30 p.m. ET. Investors can access live audio webcasts and replays via the Investors section on BioCryst's website. The company focuses on developing oral medications for rare diseases, including ORLADEYO™ for HAE attack prevention and other investigational therapies.

BioCryst Pharmaceuticals (BCRX) announced that the UK’s MHRA has granted marketing authorization for ORLADEYO™ (berotralstat) as the first oral therapy for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older. This approval marks a significant step in providing patients with a convenient treatment option, potentially improving their quality of life. Clinical trial data showed ORLADEYO reduced HAE attack rates significantly, from 2.9 to 1.0 attacks per month over 48 weeks. The NICE and SMC decisions for NHS use are expected in Q4 2021.

BioCryst Pharmaceuticals reported Q1 2021 net revenue of $10.9 million from ORLADEYO, marking a strong launch for its oral treatment for hereditary angioedema (HAE) in the U.S. The drug is now approved in the U.S., Japan, and the EU. Total revenues reached $19.1 million, up from $4.8 million a year earlier. R&D expenses increased to $42.4 million, reflecting investments in the BCX9930 program. The net loss widened to $64.3 million, or $0.36 per share. With $244.4 million in cash, the company expects its resources to last into 2023.

BioCryst Pharmaceuticals (Nasdaq:BCRX) announced its participation in two upcoming virtual healthcare conferences. The company will present at the Bank of America 2021 Healthcare Conference on May 12, 2021, at 12:30 p.m. ET, and at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 1:20 p.m. ET. Interested parties can access links to live audio webcasts and replays in the Investors section of BioCryst’s website.

BioCryst focuses on discovering novel, oral medicines for rare diseases.

BioCryst Pharmaceuticals (BCRX) announced that the European Commission has approved ORLADEYO^™ (berotralstat) for preventing recurrent hereditary angioedema (HAE) attacks in patients aged 12 and older. This approval marks ORLADEYO as the first targeted oral prophylactic therapy in Europe, catering to a significant unmet need. The company plans to launch ORLADEYO in Germany this quarter, with other European markets to follow. In trials, ORLADEYO significantly reduced attack rates and was well tolerated, prompting optimism about its market acceptance and potential impact on patient care.

BioCryst Pharmaceuticals, Inc. (BCRX) will report its first quarter 2021 financial results on May 6, 2021. A conference call and webcast will occur at 8:30 a.m. ET to discuss the results and provide corporate updates. Interested parties can access the call via phone or through a live webcast on BioCryst's investor website. BioCryst focuses on developing oral, small-molecule medicines for rare diseases, with products like ORLADEYO™ approved for HAE attacks and several ongoing development programs.

BioCryst Pharmaceuticals announced that Japan's National Health Insurance (NHI) system has approved ORLADEYO (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE), making it the first approved medication of its kind in the country. The NHI price listing will trigger a $15 million milestone payment to BioCryst from its partner Torii Pharmaceutical.

Additionally, BioCryst will receive tiered royalties on net sales in Japan. The medication has shown effectiveness in clinical trials, meeting primary endpoints for reducing HAE attacks.

BioCryst Pharmaceuticals (Nasdaq:BCRX) will present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 8:45 a.m. ET. The event will be streamed live via the Investors section of BioCryst’s website, with a replay available afterward. BioCryst focuses on developing oral medications for rare diseases, with products like ORLADEYO™ approved in the U.S. and Japan for HAE attack prevention. The company also has ongoing programs for additional treatments, including BCX9930 and BCX9250, targeting various rare conditions.

BioCryst Pharmaceuticals (BCRX) announced that its oral Factor D inhibitor, BCX9930, has shown significant efficacy in increasing hemoglobin levels and reducing transfusion requirements in treatment-naïve and C5 inhibitor inadequate response patients with paroxysmal nocturnal hemoglobinuria (PNH). In the trial, 100% of treatment-naïve patients and 83% of C5 inadequate response patients were transfusion-free. The mean hemoglobin levels increased significantly, and the drug was well-tolerated. Pivotal trials are expected to commence in the second half of 2021.